Osteocalcin (1-43/49) human ELISA

This ELISA (enzyme-linked immunosorbent assay) kit is intended for measurement of both human osteocalcin (1-49) and osteocalcin (1-43) (also referred as N-terminal & mid-regional osteocalcin) levels in test samples. This test is useful for assessing the bone formation activity or osteoblast activity in individuals associated with changes in the rate of bone turnover in metabolic bone disease, such as osteoporosis, primary hyperparathyroidism, hyperthyroidism, Paget’s disease, and renal osteodystrophy.

Regulatery Status: RUO
Catalog No Size
Product Catalog No: EIA-5504 Pack Size: 96 Wells

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Test Principle

This ELISA is designed, developed and produced for measurement of human osteocalcin (1-49) and (1-43) in serum or plasma sample.

The assay utilizes the two-site “sandwich” technique with two selected antibodies that bind to different epitopes of human osteocalcin.

Assay standards, controls and specimen samples are added directly to wells of a microtiter plate that is coated with streptavidin. Subsequently, a mixture of biotinylated human osteocalcin N-terminal region specific polyclonal antibody and a peroxidase-labeled human osteocalcin 20 – 43 region specific monoclonal antibody is added to each well. After the first incubation period, a “sandwich” of “biotinylated antibody – human osteocalcin – HRP-monoclonal antibody” is formed and this immunocomplex is also captured to the wall of microtiter plate via a streptavidin-biotin affinity binding. The unbound monoclonal antibodies and buffer matrix are removed in the subsequent washing step. A substrate solution in a timed reaction is then measured in a spectrophotometric microplate reader. The enzymatic activity of the immunocomplex bound to the wall of each microtiter well is directly proportional to the amount of human osteocalcin in a test sample. A standard curve is generated by plotting the absorbance versus the respective human osteocalcin concentration for each standard on point-to-point or 4 parameter curve fit. The concentration of human osteocalcin in test samples is determined directly from this standard curve.

Order Enquiry

Order Enquiry Form

References
  • Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem. 1995 Oct;41(10):1439-45.
  • Takahashi M, Kushida K, Nagano A, Inoue T. Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta. 2000 Apr;294(1-2):67-76.
  • Nagasue K, Inaba M, Okuno S, Kitatani K, Imanishi Y, Ishimura E, Miki T, Kim M, Nishizawa Y. Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients. Biomed Pharmacother. 2003 Mar;57(2):98-104.
  • Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res. 1994 Feb;9(2):255-64
Documents
Enquiry